EGFR and cancer: Our global analysis of chemosensitivity suggest that IAPs may be good biomarkers for sensitivity of ERK-MAPK inhibitors in multiple cancers including 3 types of lung cancers and possible biomarkers of sensitivity to EGFR inhibitor, PI3K/MTOR inhibitor and WNT signaling inhibitor for cancers resistant to ERK-MAPK inhibition.